Sangon Biotech: difference between revisions
Diff·revision 3 → 4·06:28, 23 Dec 2024
Difference between revision 3 and revision 4 of Sangon Biotech. 2 lines changed; the page grew by 283 bytes.
| Revision 3 — 22:53, 17 Dec 2024 BlindSampleBrid (talk) fix hyphenation per PP:MOS 2,171 bytes +38 | Revision 4 — 06:28, 23 Dec 2024 StubSorterBot (talk) bot: normalise citation format 2,454 bytes +283 | ||
|---|---|---|---|
| 13 | Incorporated in 2004, the organisation has one of the longer histories among the entities covered here.{{r|registry}} Its catalogue is notably broader than the research-peptide sector norm, extending into general laboratory reagents, oligonucleotides and molecular-biology consumables, and its name appears in technical contexts unrelated to the research-compound trade.{{r|selfpub}} | 13 | Incorporated in 2004, the organisation has one of the longer histories among the entities covered here.{{r|registry}} Its catalogue is notably broader than the research-peptide sector norm, extending into general laboratory reagents, oligonucleotides and molecular-biology consumables, and its name appears in technical contexts unrelated to the research-compound trade.{{r|selfpub}} |
| 14 | 14 | ||
| + | 15 | That breadth is the strongest element of its notability case and also the source of a scope question editors have discussed: an organisation whose peptide business is one line among many is not primarily a peptide supplier, and an article that treats it as one distorts what it is. | |
| + | 16 | ||
| 15 | == References == | 17 | == References == |
| 16 | {{reflist}} | 18 | {{reflist}} |